 |
The Journal of the Japanese Society for Clinical Microbiology |
Biblioraphy Information
| ArticleTitle |
Six cases of POM-1 metallo-β-lactamase producing Pseudomonas otitidis isolated from clinical specimens |
| Language |
J |
| AuthorList |
Naoya Nishiyama1), Kohei Uechi1,2), Takaaki Tome2), Maria Shimoji2), Takeya Ohshiro3), Masashi Nakamatsu1), Takeshi Kinjo1), Masao Tateyama1), Jiro Fujita1) |
| Affiliation |
1) Department of Infectious, Respiratory and Digestive Medicine, Graduate School of Medicine, University of the Ryukyus, Okinawa, Japan
2) Division of Clinical Laboratory and Blood Transfusion, University of the Ryukyus Hospital, Okinawa, Japan
3) Division of Clinical Laboratory, Department of Medical Technology, Naha City Hospital, Okinawa, Japan |
| Publication |
J.J.C.M.: 29 (2), 73-77, 2019 |
| Received |
July 3, 2018 |
| Accepted |
October 31, 2018 |
| Abstract |
Pseudomona otitidis was first described in 2006 as a causative agent of otic infections. Here, we report six cases of P. otitidis isolated from clinical specimens (three from sputum, two from otorrhea, one from stool). Isolates were originally misidentified by morphological and biochemical characters as P. aeruginosa or P. putida. However, analysis of 16S rRNA sequences and using the MALDI-TOF MS system revealed our isolates to be P. otitidis. All strains were susceptible to piperacillin and antipseudomonal cephalosporins, although resistance or decreased susceptibility to carbapenems was observed. P. otitidis has a resident metallo-β-lactamase (MBL) gene and produces an MBL, named POM-1. When Pseudomonas isolates show unusual β-lactam susceptibility, physicians should suspect P. otitidis and use carbapenem-based regimens with caution. |
| Keywords |
Pseudomonas otitidis, POM-1, MALDI-TOF MS |
|
